Taysha Gene Therapies revenue was $8.33M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $2.0M, up 13.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TSHA annual revenue was $8.3M, with -46.1% growth year-over-year.
TSHA past revenue growth
How has TSHA's revenue growth performed historically?
On Invalid Date, Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 2024 revenue of $2.02 million up 43.9% year over year. In the same quarter last year, Taysha Gene Therapies's revenue was $3.60 million.
What was Taysha Gene Therapies's revenue in 2024?
Taysha Gene Therapies's annual revenue for the twelve months ending Dec 31, 2024 was $8.33 million, a 46.07% decrease year over year.
How much does Taysha Gene Therapies make in a day?
Based on Taysha Gene Therapies annual revenue for the past four years, TSHA makes an average of $18,004.11 per day.
What was Taysha Gene Therapies's annual revenue growth in the past year?
As of Q1 2025, Taysha Gene Therapies's revenue has grown -46.07% year over year. This is 467.5 percentage points lower than the US Biotechnology industry revenue growth rate of 421.43%. Taysha Gene Therapies's revenue in the past year totaled $8.33 million.
How much does Taysha Gene Therapies make in a year?
Taysha Gene Therapies's revenue by year for the past four years is:
Taysha Gene Therapies's revenue for the twelve months ending Dec 31, 2024 was $8.33 million, a 46.07% decrease year over year.
Taysha Gene Therapies's annual revenue for Dec 31, 2023 was $15.45 million, a 517.55% increase from 2022.
Taysha Gene Therapies's annual revenue for 2022 was $2.50 million, a Infinity% increase from 2021.
Taysha Gene Therapies's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.